Sanofi SNY · NASDAQ
$41.60 -0.86% (-$0.36)
Summary
62 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 EUR of revenue, 24 EUR is left as free cash.
- It bought back its own shares for 5.68B € in the last fiscal year, 6.7% of its market value.
What to watch
- It pays out more in dividends than it earns: 131% of profit.
- It earns only 5.3 EUR a year on every 100 EUR of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.4 EUR for 1 EUR of yearly profit. Over the last five years it was 17.2 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 4.6% a year over 5 years. Over the last 3 years it grew by 4.8% a year. For the next fiscal year analysts expect revenue to grow by 2.1%. Earnings per share grew by 0.2% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 27 EUR
- Research and development 17 EUR
- Sales and administration 42 EUR
- Taxes and other 6.7 EUR
- Net profit 8.1 EUR
Net profit, industry median (Drug Manufacturers - General) 14 EUR
Out of every 100 EUR of revenue, 8.1 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 6.11%
- Paid out of profit
- 131%
- Raised in a row
- 3 years
You receive $2.42 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 12
- Hold 14
- Sell 1
Today's price within the analysts' price targets
The average target of $49.5 is 19% above today's price. 44% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Reportable Geographical Zones 76%
- Europe 16%
- CHINA 4.6%
- FRANCE 3.0%
Reportable Geographical Zones brings in 76% of revenue.
Segments in detail